Q-omics provides the consensus-scored LATS2 profile across patient tissues and cancer cell-line models. LATS2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LATS2 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, LATS2 RNA expression shows 19,822 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where LATS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LATS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LATS2 survival associations across molecular data types. LATS2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LATS2 RNA expression–survival associations across cancer types. High LATS2 expression shows unfavorable associations in CESC, BLCA, LGG, LUAD and DLBC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LATS2 RNA expression.
This table summarizes LATS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LATS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LATS2 shows lower tumor expression in THCA, KICH, BLCA, LUAD and LUSC and higher tumor expression in HNSC. The THCA box plot shows higher LATS2 RNA expression in normal versus tumor tissue (log2 FC = −1.725, t-test p < 0.001).
This table shows molecular features associated with LATS2 in patient tissues and cancer cell lines. In patient samples, LATS2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LATS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
